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INTRODUCTION
It has recently been suggested that high-dose immunosup-
pressive treatment (HDIT) with autologous stem cell trans-
plantation (ASCT) can be an alternative therapeutic modali-
ty for the management of severe autoimmune diseases (1-5).
Rheumatoid arthritis (RA) is one of the most common sys-
temic autoimmune diseases in which morbidity is substan-
tial and current treatment often remains unsatisfactory. There-
fore, refractory RA has been regarded as a possible candidate
for HDIT with ASCT (6-9). Here, we report a case of HDIT
with ASCT in the treatment of 54-yr-old patient with refrac-
tory RA.
CASE REPORT
A 54-yr-old woman had been suffering from erosive, sero-
positive, polyarticular rheumatoid arthritis for 10 yr, which
was resistant to available antirheumatic agents. She had pre-
viously been treated unsuccessfully with each of the follow-
ing disease-modifying antirheumatic drugs (DMARDs): hy-
droxychloroquine (HCQ, 400 mg/day), methotrexate (MTX,
17.5 mg/week), sulfasalazine (SSZ, 2.0 g/day), and bucillamine
(200 mg/day). She also underwent multiple combination
therapy (HCQ+SSZ+MTX), but she did not receive cyclo-
sporin due to severe gastrointestinal discomfort. She had also
been treated with concomitant use of glucocorticoids, which
was ineffective. The patient underwent right shoulder and
left elbow replacements for the complications resulting from
RA. Multiple intraarticular glucocorticoid injections were
made, but no significant improvement was noticed through-
out the entire disease course. On first admission, her Ritchie
Articular Index (RAI) was 26. The number of tender joints
(68 joints total) and swollen joints (66 joints total) was 27
and 22, respectively. The patient’ s global assessment of dis-
ease status was 95% (0% is best and 100% is worst). The
physician’ s global assessment of disease status was 85% (0%
is best and 100% is worst). The patient’ s assessment of physi-
cal function according to the Korean Health Assessment
Questionnaire (KHAQ) was 3.2 (10). The C-reactive protein
(CRP) and erythrocyte sedimentation rate (ESR) were 3.63
mg/dL and 32 mm/hr, respectively. Other laboratory find-
ings were as follows: leukocyte 6,100/ L, hemoglobin 12.3
g/dL, hematocrit 38.4%, platelet 304,000/ L, total protein
6.6 g/dL, albumin 3.5 g/dL, creatinine 0.8 mg/dL, ALT/
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Autologous Stem Cell Transplantation in the Treatment of Refractory
Rheumatoid Arthritis 
The concept of using high-dose immunosuppressive treatment (HDIT) with autol-
ogous stem cell transplantation (ASCT) to treat patients with refractory rheuma-
toid arthritis has been provided by animal studies and anecdotal case reports.
Over the past five years, an increasing number of patients with refractory rheuma-
toid arthritis have received HDIT with ASCT as an adjunct to intense immuno-
suppression. Here, we present a case of refractory rheumatoid arthritis in a 54-yr-
old woman using HDIT with ASCT. Peripheral blood stem cells were mobilized
with cyclophosphamide (4 g/m
2) followed by G-CSF (5 g/kg/day). Leukaphere-
sis continued daily until the number of harvested progenitor cells reached 2×10
6
CD34+ cells/kg after CliniMax
� CD34+ positive selection. For HDIT, high-dose
cyclophosphamide (total dose 200 mg/kg) and antithymocyte globulin (total dose
90 mg/kg) were administered and CD34+ cells were infused 24 hr after HDIT. The
patient tolerated the treatment well but experienced an episode of neutropenic
fever. She achieved an early dramatic improvement of joint symptoms during
therapy. Fifty percent of improvement of rheumatoid arthritis by the American
College of Rheumatology (ACR 50) preliminary definition was fulfilled during the
6 months following ASCT. Although further long-term follow-up is required, the
patient’ s activity of arthritis has been stable since receiving HDIT with ASCT. 
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Fig. 1. Clinical courses of the patient after autologous stem cell transplantation. (A) Number of tender joints (of 68 examined), (B)
Number of swollen joints (of 66 examined), (C) Patient’ s self assessment of disease status (0% is best and 100% is worst), (D) Physi-
cian’ s global assessment of disease status (0% is best and 100% is worst), (E) Mean K-HAQ Activities of Daily Living (ADL) score,
(F) Erythrocyte sedimentation rate and the C-reactive protein.
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AST 10/14 IU/L, and rheumatoid factor 161 IU/L. 
The protocol was approved by the Institutional Review
Board of HUKH (Hanyang University Kuri Hospital, Korea)
and the patient provided written informed consent.
Peripheral blood stem cells were mobilized with cyclophos-
phamide (CTX, 4 g/m2), followed by granulocyte-colony
stimulating factor (G-CSF, 5 g/kg/day). Leukapheresis was
initiated on day 12 when the leukocyte count was above
1,000/ L by CS3000
� (Baxter, U.S.A.) for 2 days until
CD34+ cells reached 2×106 cells/kg. For CD34 positive
selection, the CliniMax
�column (Am Cell Corporation, Sun-
nyvale, U.S.A.) was used. A month after leukapheresis, the
patient was readmitted to undergo autologous stem cell trans-
plantation (ASCT). Cyclophosphamide (total dose 200 mg/
kg) was administered in doses of 50 mg/kg/day intravenously
for 4 days. Antithymocyte globulin (ATG, total dose 90 mg/
kg) was infused at a doses of 30 mg/kg/days. Methylpred-
nisone was administered intravenously for 30 min before each
dose of ATG. Forty-eight hours after HDIT, stored CD34+
stem cells were infused via central route and G-CSF (5  g/
kg/day) was administered subcutaneously until the absolute
neutrophil count was greater than 1,000/ L for 3 consecu-
tive days. The numbers of infused CD34+ cells were 2.12
×106 cells/kg. The patient tolerated relatively well to the
treatment with WHO grade II nausea, vomiting, and skin
rash. An episode of neutropenic fever was controlled with
empirical antibiotics. The patient achieved a neutrophil
count greater than 1,000/ L by day 12. There was no epi-
sode of thrombocytopenia and no requirement of packed red
cell transfusion. As soon as the administration of HDIT and
ASCT was finished, the clinical improvement of RA activi-
ty was evident. Follow-up clinical assessment was done, six
months after treatment. Her RAI decreased to 5. The num-
bers of tender and swollen joint counts decreased to 3 and 0,
respectively. The patient’ s global assessment of disease status
decreased to 20%. The physician’ s global assessment of dis-
ease status was 20%. The patient’ s assessment of physical
function according to the Korean Health Assessment of
Questionaire (KHAQ) was 1.6. Her acute phase reactant
values of CRP and ESR were 2.63 mg/dL and 53 mm/hr,
respectively. The joint symptom was satisfactorily controlled
by the sole use of a nonsteroidal antiinflammatory agent
(nabumetone, 1,000 mg/day).
The American College of Rheumatology (ACR) prelimi-
nary definition of 50% improvement of RA (ACR50) was
fulfilled during the 6 months following ASCT (Fig. 1) (11).
Although further long-term follow-up is required, the pa-
tient’ s activity of arthritis has been stable since receiving
HDIT with ASCT.Autologous Stem Cell Transplantation in Refractory Rheumatoid Arthritis      131
DISCUSSION
Over the past five years, an increasing number of patients
with autoimmune disease have received HDIT with ASCT.
Over 200 transplants have been reported to a registry devel-
oped jointly by the European Group for Blood and Marrow
Transplantation (EBMT) and the European League Against
Rheumatism (EULAR). Approximately 11% of these trans-
plants have been performed for rheumatoid arthritis (RA)
(12). 
The use of this new treatment has changed from a concept
to an undergoing clinical trial. Most reports have emphasized
the findings that ASCT can replace disease-causing lympho-
cytes with normal ones. High-doses of CTX are given to pa-
tients to wipe out the  “bad” lymphocytes. However, since
CTX in high doses has been erroneously believed to destroy
the bone marrow’ s ability to make new blood cells, the method
also requires a blood stem cell transplant to prevent this dis-
aster. 
Although the population kinetics of synovial cells are not
completely understood, many evidences suggest a bone mar-
row origin for at least that synovial cell subset which is phe-
notypically similar to macrophages (13). Although it is not
clear whether this applies to all synovial cells, other data sug-
gest that there is local proliferation of at least the fibroblast-
like synovial cells (14). 
The rationale behind HDIT includes; 1) inhibition of the
proliferation of synovial cells, 2) induction of apoptosis in
synovial cells, 3) decreasing the bone marrow pool of a pop-
ulation of cells destined to become synovial cells (15). Another
possible cure for RA could be brought about through the eli-
mination and prevention of the reemergence of the  “wrong”
macrophages, dendritic cells, and B cells, and through the
reverse of the abnormal synovial microenvironment. Although
the exact mechanism of HDIT with ASCT on RA treatment
has not been fully understood, the rationale is probably to
reset the stem cells so that random rearrangements of T-cell
and B-cell receptors after autologous transplant would result
in a more favorable immunologic repertoire (16). 
Despite the difference of CTX doses and the stem cell mo-
bilization prorocols, recurrence of disease was noted for all
patients, although favorable responses were observed, initially
(17, 18). The recurrence rate of RA following HDIT/ ASCT
is not clear, but the mechanism has been proposed in several
reports. They suggest that relapse of RA may be inevitable
if chemotherapy-resistant, antigen-presenting cells remain
in the synovium, or if circulating T cells that survive HDIT,
are infused with the ASCT. Also, the T cells from the rede-
veloping immune system may arrive at the injured joints
and develop into cells that react to arthritogenic peptides
remaining in the joint. Therefore, our experience of HDIT/
ASCT on refractory RA warrants careful monitoring at least
for 12 months after the procedure, even though an initial
clinical improvement was achieved. 
To prolong the period of complete remission, allogeneic
stem cell transplantation may be preferable to autologous
since allogeneic cells could conceivably play a role in eradi-
cating abnormal immune cell population (19). Since patients
undergoing allogeneic stem cell transplantation are more
prone to graft-versus-host disease, infection, bleeding, and
are associated with high treatment-related mortality, the
procedure is not popular for the treatment of autoimmune
disease. However, recently developed approach with non-
myeloablative allogeneic stem cell transplantation can sub-
stantially reduce treatment-associated toxicity and might be
a useful treatment modality (20). 
Another limitation of HDIT/ASCT on refractory RA is
long-term morbidity and mortality. Some reports have ad-
dressed the possible developments of neoplasia, either solid
tumors or hematologic malignancies (21, 22). Other com-
plications include infertility, early menopause, and cataracts.
Short-term side effects (e.g., mucositis, nausea/vomiting, or
neutropenic fever) were more readily controlled compared
to long-term morbidity. In transplant data reported to the
EBMT-EULAR registry, an 8-9% treatment mortality has
been observed for autoimmune disease (2). 
Still a number of issues remain to be clarified regarding
HDIT/ASCT in the treatment of autoimmune disease. Patient
selection is important, and should be done with a reliable
identification of what currently available treatment regimens
have failed in the patient prior to the entry into these stud-
ies. The issue of how to mobilize stem cells may need to be
clarified and conditioning regimens also need to be standard-
ized (23). Lastly, the development of appropriate trials is
mandatory, which would compare HSCT/ASCT to standard
and molecular therapies. Furthermore, multi-center based
studies and consensus should be developed for protocol de-
sign and end point measurement. After such considerations,
HDIT/ASCT will settle down as a more optimal modality
in the treatment of RA.
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